5 recruiting, 1 completed, 1 not yet recruiting. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 5, Completed 1, Not yet recruiting 1 |
| Phase 2 | 4 | Recruiting 3, Not yet recruiting 1 |
Follow Systemic Lupus Erthematosus: new trials by email Literature Review of Systemic Lupus Erthematosus trials Research Report on Systemic Lupus Erthematosus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) Budoprutug - Systemic Lupus Erthematosus | Phase 1 / Phase 2 | Recruiting | Climb Bio, Inc. | 30 | 2026-06-30 | 2026-10-20 |
| A Study of GR1803 in Systemic Lupus Erythematosus GR1803 injection - Systemic Lupus Erthematosus, Auto Immune Disease | Phase 1 / Phase 2 | Recruiting | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 44 | 2026-02-02 | 2026-03-10 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus BCD-256, Divozilimab - Systemic Lupus Erthematosus | Phase 1 | Recruiting | Biocad | 135 | 2025-03-27 | 2025-08-22 |
| UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients Physical examination, Electrocardiogram, SF-36 questionnaire - SLE, Lupus | Phase 1 | Recruiting | LiveKidney.Bio | 10 | 2025-01-07 | 2025-09-11 |
| Omalizumab for Lupus Omalizumab - Systemic Lupus Erthematosus, Sjogren's Syndrome | Phase 1 | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 17 | 2014-01-08 | 2022-04-20 |
Lupus Erythematosus, Systemic (3) · Sjogren's Syndrome (3) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · Myositis (2) · Scleroderma, Systemic (2) · Antiphospholipid Syndrome (1)
Autoimmune Diseases (5) · Connective Tissue Diseases (5) · Immune System Diseases (5) · Skin and Connective Tissue Diseases (5) · Arthritis (3) · Arthritis, Rheumatoid (3) · Dry Eye Syndromes (3) · Eye Diseases (3) · Joint Diseases (3) · Lacrimal Apparatus Diseases (3) · Mouth Diseases (3) · Musculoskeletal Diseases (3) · Rheumatic Diseases (3) · Salivary Gland Diseases (3) · Stomatognathic Diseases (3)
Electrocardiography (1) · Omalizumab (1) · Physical Examination (1) · Pregnancy Tests (1) · Urinalysis (1)
Peking University Third Hospital (2) · Biocad (1) · Climb Bio, Inc. (1) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1) · LiveKidney.Bio (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)
China (3) · United States (2) · Russia (1)
Arina V Zinkina-Orikhan, PhD (1) · Sarfaraz A Hasni, M.D. (1)